個別化医療の市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント予測、2024年～2030年

個別化医療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の個別化医療市場規模は2030年までに9,098億米ドルに達し、2024年から2030年までのCAGRは8.20％で拡大すると予測されています。

同市場は、疾病の発生率の増加と新規治療薬に対する需要の高まりにより、2023年から2030年にかけてCAGR 7.20％を記録すると予測されています。個別化医療の新たな応用は、膨大な研究努力によって一貫して強化されています。例えば、2022年7月、UMass Chan Medical Schoolの研究者は、個人のゲノム、食事、微生物叢、関連する環境因子との関連を測定するために、代謝の変動の理解を助ける微生物ベースの個別化医療モデルシステムを開発しました。

ほとんどのがんは、遺伝的な不一致によって引き起こされ、進行すると致命的な症状を引き起こします。特定のゲノム特性を理解することで、がんの状態を効果的かつ正確に治療することができます。例えば、2020年5月、キアゲンはQIAseq pan-cancer multi-modal panelを発売し、固形がんやヘム悪性腫瘍のプロファイリングに向けた精密医療への幅広い応用を導き出すため、がん被験者のゲノム特性のロバストな解析を可能にしました。

市場は、NGS技術の進歩やヒトゲノムに関する広範な調査によって積極的に牽引されています。がんや希少遺伝性疾患の治療に使用できる可能性のある個別化医療の成果を導き出すためにNGSを活用することにますます注目が集まっています。例えば、イルミナは、パリで開催される欧州腫瘍学会（ESMO）年次総会で複数の腫瘍学研究のアブストラクトを発表すると宣言しました。イルミナの調査は、生検の包括的なゲノムプロファイリングを用いて、被験者を潜在的な薬剤や免疫療法に適合させることで、個別化がん治療を可能にします。

遠隔医療は、物理的な利便性を補助するために、バーチャルまたは電話による臨床アドバイスを容易にします。遠隔医療は、特にCOVID-19パンデミック以降、ますます動向を見せています。政府や研究機関は、個別化遠隔医療の応用を強化するために多大な努力を払っています。例えば、2022年8月、米国国立がん研究所は、米国全土の遠隔医療研究センター（Telehealth Research Centers of Excellence：TRACE）の立ち上げを支援するため、5年間で2,300万米ドルの助成を宣言しました。

分子イメージングシステムと医療機器は、個別化医療の新たな進歩において主要な役割を果たしています。分子イメージング・システムと医療機器は、さまざまな種類のがんの治療において、個別化医療の応用を効果的に活用しています。例えば、2022年6月、GEヘルスケアは、前立腺がんの診断とモニタリングにガリウム-68放射性同位元素を用いたハイエンド分子イメージングを発表しました。

同市場は、新たな技術的進歩に加え、提携や事業拡大などの一貫した産業努力により成長段階にあります。例えば、2021年12月、Biogen Inc.とTheraPanacea社は、神経科学における個別化医療のためのデジタルヘルスの進展に焦点を当てた提携を締結したと宣言しました。

個別化医療市場レポートハイライト

• 同市場の全体的な成長は、遺伝子レベルでの疾患理解や、世界のがんや遺伝性疾患の罹患率の上昇を活用した新規治療薬に対するニーズの高まりに起因しています。
• 個別化医療治療薬セグメントは、バイオ医薬品開発のための薬理ゲノミクスの広範な利用により、予測期間中に高い成長が見込まれます。さらに、ゲノム治療薬セグメントは、全ゲノムシーケンスのコストが大幅に低下することから、予測期間中に大幅な成長が見込まれています。
• 北米は、主要企業が存在し、さまざまな疾患の治療法を見出すための新規治療開発のための集中的な研究を行っているため、2023年の市場を独占しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 個別化医療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 個別化医療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 個別化医療市場： 製品推定・動向分析

• 製品市場シェア、2023年および2030年
• セグメントダッシュボード
• 製品別世界個別化医療市場展望
• 2018年～2030年の市場規模と予測および動向分析

第5章 個別化医療市場： 最終用途の推定・動向分析

• メソッド市場シェア、2023年と2030年
• セグメントダッシュボード
• 最終用途別世界の個別化医療市場展望
• 2018年～2030年の市場規模と予測および動向分析

第6章 個別化医療市場：地域推定・動向分析

• 地域別市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界地域市場スナップショット
• 市場規模、予測動向分析、2018年～2030年
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • List of key distributors and channel partners
  • Key customers
  • Key company market share analysis, 2023
  • GE Healthcare
  • Illumina, Inc.
  • ASURAGEN, INC.
  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Danaher Corporation（Cepheid, Inc.）
  • Decode Genetics, Inc.
  • QIAGEN
  • Exagen Inc.
  • Precision Biologics
  • Celera Diagnostics LLC
  • Biogen
  • Genelex
  • IBM
  • Genentech, Inc.
  • 23andMe, Inc.

List of Tables

• Table 1 List of Abbreviation
• Table 2 North America Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
• Table 3 North America Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 4 North America Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 5 U.S. Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 6 U.S. Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 7 Canada Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 8 Canada Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 9 Europe Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
• Table 10 Europe Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 11 Europe Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 12 France Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 13 France Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 14 Germany Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 15 Germany Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 16 UK Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 17 UK Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 18 Spain Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 19 Spain Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 20 France Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 21 France Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 22 Italy Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 23 Italy Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 24 Sweden Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 25 Sweden Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 26 Norway Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 27 Norway Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 28 Denmark Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 29 Denmark Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 30 Asia Pacific Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
• Table 31 Asia Pacific Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 32 Asia Pacific Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 33 Japan Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 34 Japan Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 35 China Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 36 China Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 37 India Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 38 India Personalized Medicine Market, By End-Use, 2018 - 2030 (USD Billion)
• Table 39 South Korea Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 40 South Korea Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 41 Australia Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 42 Australia Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 43 Thailand Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 44 Thailand Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 45 Latin America Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
• Table 46 Latin America Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 47 Latin America Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 48 Brazil Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 49 Brazil Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 50 Mexico Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 51 Mexico Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 52 Argentina Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 53 Argentina Personalized Medicine Market, By End-Use, 2018 - 2030 (USD Billion)
• Table 54 MEA Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
• Table 55 MEA Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 56 MEA Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 57 South Africa Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 58 South Africa Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 59 Saudi Arabia Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 60 Saudi Arabia Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 61 UAE Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 62 UAE Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
• Table 63 Kuwait Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
• Table 64 Kuwait Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Personalized medicine market segmentation
• Fig. 8 Market snapshot, 2023
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 PESTEL analysis
• Fig. 13 Porter's five forces analysis
• Fig. 14 Global personalized medicine market, for product, 2018 - 2030 (USD Billion)
• Fig. 15 Global personalized medicine market, for diagnostics, 2018 - 2030 (USD Billion)
• Fig. 16 Global personalized medicine market, for genetic testing, 2018 - 2030 (USD Billion)
• Fig. 17 Global personalized medicine market, for direct-to-consumer (DTC) testing, 2018 - 2030 (USD Billion)
• Fig. 18 Global personalized medicine market, for esoteric lab services, 2018 - 2030 (USD Billion)
• Fig. 19 Global personalized medicine market, for esoteric lab tests, 2018 - 2030 (USD Billion)
• Fig. 20 Global personalized medicine market, for therapeutics, 2018 - 2030 (USD Billion)
• Fig. 21 Global personalized medicine market, for pharmaceutical, 2018 - 2030 (USD Billion)
• Fig. 22 Global personalized medicine market, for genomic medicine, 2018 - 2030 (USD Billion)
• Fig. 23 Global personalized medicine market, for medical devices, 2018 - 2030 (USD Billion)
• Fig. 24 Global personalized medicine market, for personalized medical care, 2018 - 2030 (USD Billion)
• Fig. 25 Global personalized medicine market, for telemedicine, 2018 - 2030 (USD Billion)
• Fig. 26 Global personalized medicine market, for health information technology, 2018 - 2030 (USD Billion)
• Fig. 27 Global personalized medicine market, for personalized nutrition & wellness, 2018 - 2030 (USD Billion)
• Fig. 28 Global personalized medicine market, for retail nutrition, 2018 - 2030 (USD Billion)
• Fig. 29 Global personalized medicine market, for complementary & alternative medicine, 2018 - 2030 (USD Billion)
• Fig. 30 Global personalized medicine market, for End-use, 2018 - 2030 (USD Billion)
• Fig. 31 Global personalized medicine market, for diagnostics centers, 2018 - 2030 (USD Billion)
• Fig. 32 Global personalized medicine market, for academic and research institutes, 2018 - 2030 (USD Billion)
• Fig. 33 Global personalized medicine market, for hospitals, 2018 - 2030 (USD Billion)
• Fig. 34 Global personalized medicine market, for others, 2018 - 2030 (USD Billion)
• Fig. 35 Regional outlook, 2023 & 2030
• Fig. 36 North America personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 37 U.S. personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 38 Canada personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 39 Europe personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 40 Germany personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 41 UK personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 42 France personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 43 Italy personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 44 Spain personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 45 Denmark personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 46 Sweden personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 47 Norway personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 48 Asia Pacific personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 49 Japan personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 50 China personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 51 India personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 52 Australia personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 53 Thailand personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 54 South Korea personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 55 Latin America personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 56 Brazil personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 57 Mexico personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 58 Argentina personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 59 MEA personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 60 South Africa personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 61 Saudi Arabia personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 62 UAE personalized medicine market, 2018 - 2030 (USD Billion)
• Fig. 63 Kuwait personalized medicine market, 2018 - 2030 (USD Billion)

Personalized Medicine Market Growth & Trends:

The global personalized medicine market size is expected to reach USD 909.80 billion by 2030, expanding at a CAGR of 8.20% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 7.20% from 2023 to 2030 owing to the increasing incidence of diseases and the rising demand for novel therapeutic drugs. The emerging applications of personalized medicine are consistently enhanced by immense research efforts. For instance, in July 2022, researchers at the UMass Chan Medical School developed a microorganism-based personalized medicine model system to aid the understanding of variation in metabolism to gauge the connection between an individual's genome, diet, microbiota, and associative environmental factors.

Most cancer conditions are usually caused by an underlying genetic discrepancy and can cause fatalities with progression. The cancer condition can be effectively and precisely treated by understanding specific genomic characteristics. For instance, in May 2020, Qiagen launched QIAseq pan-cancer multi-modal panel to enable robust analysis of genomic characteristics of cancer subjects to derive a broad spectrum of applications in precision medicine for the profiling of solid tumors and heme malignancies.

The market is positively driven by advancements in NGS technologies and extensive research on the human genome. There has been an increasing focus on utilizing NGS to derive personalized medicine outcomes that could potentially be used for the treatment of cancer and rare genetic disorders. For instance, Illumina declared that it will present its multiple oncology research abstracts at the European Society of Medical Oncology (ESMO) annual meeting in Paris. Their research enables personalized cancer care using comprehensive genomic profiling of biopsies to match subjects to the potential drugs and immunotherapies.

Telemedicine facilitates virtual or telephonic clinical advice to aid physical convenience. Telemedicine is increasingly trending, especially after the COVID-19 pandemic. Government and research institutes are taking substantial efforts to enhance the applications of personalized telemedicine. For instance, in August 2022, the National Cancer Institute declared a grant of USD 23 million for five years to aid the launch of Telehealth Research Centers of Excellence (TRACE) across the U.S. The program was launched with the support of the White House Cancer Moonshot to seek development and advancements in telehealth delivery for cancer care with a mission to leverage health equity.

Molecular imaging systems and medical devices are playing a primary role in emerging advancements in personalized medicine. They effectively leverage the applications of personalized medicine in the treatment of different types of cancers. For instance, in June 2022, GE Healthcare declared the release of high-end molecular imaging by using gallium-68 radioisotope for the diagnosis and monitoring of prostate cancer so as to leverage access to precision health and theranostics for personalized prostate cancer treatment at an early stage of cancer progression.

The market is in the growth phase due to emerging technological advancements along with consistent industrial efforts such as collaborations and expansions. For instance, in December 2021, Biogen Inc., and TheraPanacea declared that they have signed a collaboration that focuses on advancing digital health for personalized medicine in neuroscience.

Personalized Medicine Market Report Highlights:

• The overall growth of the market is attributed to the rising need for novel therapeutic drugs coupled with leveraged genetic level understanding of diseases and the rising incidence of cancers and genetic disorders across the globe
• The personalized medicine therapeutics segment is anticipated to witness high growth over the forecast period owing to the extensive usage of pharmacogenomics for developing biopharmaceuticals. Further, the genomic medicine therapeutics segment is anticipated to grow substantially during the forecast period owing to significantly lowered costs of whole-genome sequencing
• North America dominated the market in 2023 due to the presence of key players and their intensive research for the development of novel therapies to find out curative solutions for various diseases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End-use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. End-use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Personalized Medicine Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in next-generation sequencing technology
    • 3.2.1.2. Expanding portfolio of companion/associated diagnostics
    • 3.2.1.3. Increasing prevalence of cancer & usage of biomarkers for personalized medicine cancer therapy
    • 3.2.1.4. Technological advancements to facilitate R&D for personalized medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Presence of nonvalue-based personalized medicine diagnostics reimbursement policy
    • 3.2.2.2. Lack of proper intellectual property regulations for personalized medical technologies
• 3.3. Personalized Medicine Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Personalized Medicine Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Personalized Medicine Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Personalized Medicine Diagnostics
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.1.2. Genetic Testing
    • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.1.3. DTC Diagnostics
    • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.1.4. Esoteric Lab Services
    • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.1.5. Esoteric Lab Tests
    • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.2. Personalized Medicine Therapeutics
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2.2. Pharmaceutical
    • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2.3. Genomic Medicine
    • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2.4. Medical Devices
    • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.3. Personalized Medical Care
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3.2. Telemedicine
    • 4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3.3. Health Information Technology
    • 4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.4. Personalized Nutrition & Wellness
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4.2. Retail Nutrition
    • 4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4.3. Complementary & Alternative Medicine
    • 4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Personalized Medicine Market: End-use Estimates & Trend Analysis

• 5.1. Method Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Personalized Medicine Market by End-use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Hospitals
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.2. Academic & Research Institutes
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.3. Diagnostic Centers
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.4. Others
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Personalized Medicine Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8.2. Mexico
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. GE Healthcare
    • 7.3.4.1. Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Product Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. Illumina, Inc.
    • 7.3.5.1. Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Product Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. ASURAGEN, INC.
    • 7.3.6.1. Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Product Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. Abbott
    • 7.3.7.1. Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Product Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. Dako A/S
    • 7.3.8.1. Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Product Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Exact Sciences Corporation
    • 7.3.9.1. Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Product Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. Danaher Corporation (Cepheid, Inc.)
    • 7.3.10.1. Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Product Benchmarking
    • 7.3.10.4. Strategic Initiatives
  • 7.3.11. Decode Genetics, Inc.
    • 7.3.11.1. Overview
    • 7.3.11.2. Financial Performance
    • 7.3.11.3. Product Benchmarking
    • 7.3.11.4. Strategic Initiatives
  • 7.3.12. QIAGEN
    • 7.3.12.1. Overview
    • 7.3.12.2. Financial Performance
    • 7.3.12.3. Product Benchmarking
    • 7.3.12.4. Strategic Initiatives
  • 7.3.13. Exagen Inc.
    • 7.3.13.1. Overview
    • 7.3.13.2. Financial Performance
    • 7.3.13.3. Product Benchmarking
    • 7.3.13.4. Strategic Initiatives
  • 7.3.14. Precision Biologics
    • 7.3.14.1. Overview
    • 7.3.14.2. Financial Performance
    • 7.3.14.3. Product Benchmarking
    • 7.3.14.4. Strategic Initiatives
  • 7.3.15. Celera Diagnostics LLC
    • 7.3.15.1. Overview
    • 7.3.15.2. Financial Performance
    • 7.3.15.3. Product Benchmarking
    • 7.3.15.4. Strategic Initiatives
  • 7.3.16. Biogen
    • 7.3.16.1. Overview
    • 7.3.16.2. Financial Performance
    • 7.3.16.3. Product Benchmarking
    • 7.3.16.4. Strategic Initiatives
  • 7.3.17. Genelex
    • 7.3.17.1. Overview
    • 7.3.17.2. Financial Performance
    • 7.3.17.3. Product Benchmarking
    • 7.3.17.4. Strategic Initiatives
  • 7.3.18. IBM
    • 7.3.18.1. Overview
    • 7.3.18.2. Financial Performance
    • 7.3.18.3. Product Benchmarking
    • 7.3.18.4. Strategic Initiatives
  • 7.3.19. Genentech, Inc.
    • 7.3.19.1. Overview
    • 7.3.19.2. Financial Performance
    • 7.3.19.3. Product Benchmarking
    • 7.3.19.4. Strategic Initiatives
  • 7.3.20. 23andMe, Inc.
    • 7.3.20.1. Overview
    • 7.3.20.2. Financial Performance
    • 7.3.20.3. Product Benchmarking
    • 7.3.20.4. Strategic Initiatives